Nifekalant

Abstract

Atrial fibrillation along with accessory pathway–induced ventricular pre-excitation may be life-threatening due to the high risk of developing severe hypotension, ventricular fibrillation, and sudden death. We demonstrate nifekalant as an effective agent in the pharmacological cardioversion of atrial fibrillation with high-risk accessory pathways. (Level of Difficulty: Intermediate.)

Keywords

• atrial fibrillation
• cardioversion
• tachycardia